Kits and methods for assessing skin health
AssigneeGenelink, Inc.
InventorsJohn DePhillipo, Robert Ricciardi
Life of this patent
Estimating the term…
Abstract
The invention relates to kits and methods for assessing skin health for a human and the human's susceptibility to skin disorders. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated disclosed herein and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kits for performing the methods.
Claims27
A method of assessing skin health of a human, the method comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least two genes selected from the group consisting of
- a) the gene which encodes mitochondrial manganese superoxide dismutase (MnSOD);
- b) the gene which encodes cytoplasmic copper/zinc superoxide dismutase (CZSOD);
- c) the gene which encodes catalase;
- d) the gene which encodes human glutathione peroxidase (hGPX1);
- e) the gene which encodes glutathione S transferase P1 (GSTP1);
- f) the gene which encodes NAD(P)H:quinone oxidoreductase;
- g) the gene which encodes epoxide hydrolase;
- h) the gene which encodes tumor necrosis factor alpha (TNF-alpha);
- i) the gene which encodes NADH/NADPH oxidase p22 subunit (the phox gene);
- j) the gene which encodes nitric oxide synthase;
- k) the gene which encodes cytochrome P450;
- l) the gene which encodes matrix metalloproteinase 1 (MMP-1);
- and
- m) the gene which encodes profilagrin,
- whereby occurrence of any of the disorder-associated polymorphisms is an indication that the human has poorer skin health than a human whose genome does not comprise any of the disorder-associated polymorphisms, and whereby occurrence of a plurality of the disorder-associated polymorphisms is an indication that the human has even poorer skin health than a human whose genome does not comprise the disorder-associated polymorphisms.
10-11. (canceled)
13-17. (canceled)
20-23. (canceled)
(canceled)
(canceled)
A method of assessing the likelihood that a human will develop a skin disorder, the method comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least two genes selected from the group consisting of
- a) the gene which encodes mitochondrial MnSOD;
- b) the gene which encodes cytoplasmic CZSOD;
- c) the gene which encodes catalase;
- d) the gene which encodes hGPX1;
- e) the gene which encodes GSTP1;
- f) the gene which encodes NAD(P)H:quinone oxidoreductase;
- g) the gene which encodes epoxide hydrolase;
- h) the gene which encodes TNF-alpha;
- i) the phox gene;
- j) the gene which encodes nitric oxide synthase;
- k) the gene which encodes cytochrome P450;
- l) the gene which encodes MMP-1;
- and
- m) the gene which encodes profilagrin,
- whereby occurrence of any of the disorder-associated polymorphisms is an indication that the human is more susceptible to the skin disorder than a human whose genome does not comprise the disorder-associated polymorphism, and whereby occurrence of a plurality of the disorder-associated polymorphisms is an indication that the human is even more susceptible to the skin disorder than a human whose genome does not comprise the disorder-associated polymorphisms.
30-31. (canceled)
A method of selecting a dose of a skin protective composition for administration to a human, the method comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least two genes selected from the group consisting of
- a) the gene which encodes mitochondrial MnSOD;
- b) the gene which encodes cytoplasmic CZSOD;
- c) the gene which encodes catalase;
- d) the gene which encodes hGPX1;
- e) the gene which encodes GSTP1;
- f) the gene which encodes NAD(P)H:quinone oxidoreductase;
- g) the gene which encodes epoxide hydrolase;
- h) the gene which encodes tumor necrosis factor alpha (TNF-alpha);
- i) the phox gene;
- j) the gene which encodes nitric oxide synthase;
- k) the gene which encodes cytochrome P450;
- l) the gene which encodes MMP-1;
- and
- m) the gene which encodes profilagrin,
- whereby occurrence of any of the disorder-associated polymorphisms is an indication that a greater dose of the composition should be administered to the human;
- and selecting a dose of the composition based on occurrence of the disorder-associated polymorphisms.
A kit for assessing relative susceptibility of a human to a skin disorder, the kit comprising reagents for assessing occurrence in the human's genome of disorder-associated polymorphisms in at least two genes selected from the group consisting of
- a) the gene which encodes mitochondrial MnSOD;
- b) the gene which encodes cytoplasmic CZSOD;
- c) the gene which encodes catalase;
- d) the gene which encodes hGPX1;
- e) the gene which encodes GSTP1;
- f) the gene which encodes NAD(P)H:quinone oxidoreductase;
- g) the gene which encodes epoxide hydrolase;
- h) the gene which encodes tumor necrosis factor alpha (TNF-alpha);
- i) the phox gene;
- j) the gene which encodes nitric oxide synthase;
- k) the gene which encodes cytochrome P450;
- l) the gene which encodes MMP-1;
- and
- m) the gene which encodes profilagrin.
34-46. (canceled)
A method of assessing the advisability that a human should employ a nutritional product comprising a skin protective agent, the method comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least two genes selected from the group consisting of
- a) the gene which encodes mitochondrial MnSOD;
- b) the gene which encodes cytoplasmic CZSOD;
- c) the gene which encodes catalase;
- d) the gene which encodes hGPX1;
- e) the gene which encodes GSTP1;
- f) the gene which encodes NAD(P)H:quinone oxidoreductase;
- g) the gene which encodes epoxide hydrolase;
- h) the gene which encodes TNF-alpha;
- i) the phox gene;
- j) the gene which encodes nitric oxide synthase;
- k) the gene which encodes cytochrome P450;
- l) the gene which encodes MMP-1;
- and
- m) the gene which encodes profilagrin,
- whereby occurrence of any of the disorder-associated polymorphisms is an indication that it is more advisable for the human to employ the nutritional product than a human whose genome does not comprise the disorder-associated polymorphism, and whereby occurrence of a plurality of the disorder-associated polymorphisms is an indication that it is even more advisable that the human should employ the nutritional product than a human whose genome does not comprise the disorder-associated polymorphisms.
A method of selecting a dose of a skin protective agent for administration to a human in a nutritional product, the method comprising assessing occurrence in the human's genome of disorder-associated polymorphisms in at least two genes selected from the group consisting of
- a) the gene which encodes mitochondrial MnSOD;
- b) the gene which encodes cytoplasmic CZSOD;
- c) the gene which encodes catalase;
- d) the gene which encodes hGPX1;
- e) the gene which encodes GSTP1;
- f) the gene which encodes NAD(P)H:quinone oxidoreductase;
- g) the gene which encodes epoxide hydrolase;
- h) the gene which encodes TNF-alpha;
- i) the phox gene;
- j) the gene which encodes nitric oxide synthase;
- k) the gene which encodes cytochrome P450;
- l) the gene which encodes MMP-1;
- and
- m) the gene which encodes profilagrin,
- whereby occurrence of any of the disorder-associated polymorphisms is an indication that a greater dose of the agent should be administered to the human in the nutritional product;
- and selecting a dose of the agent for the nutritional product based on occurrence of the disorder-associated polymorphisms.
Dependencies are inferred from the claim text.